

产品名称: **Bioymifi**  
 产品别名: **DR5 Activator**

**生物活性:**

生物活性:																		
Description	<p>Bioymifi(DR5 Activator) is the first novel and potent small-molecule activator of the TRAIL receptor DR5 in human cancer cells. IC50 value: Target: In comparison with A2C2, bioymifi was able to promote cell death without the need for the Smac mimetic in T98G cells. Notably, at a 10-<math>\mu</math>M concentration, bioymifi induced processing of caspase-3 into smaller fragments. Z-VAD inhibited these caspase-mediated cleavages. caspase-3 was rapidly activated as early as 2 h after bioymifi treatment of T98G cells. The caspase-3 activity was markedly increased after 8 h of treatment. Bioymifi induces caspase-8-dependent apoptosis.</p>																	
Solvent&Solubility	<p><b><i>In Vitro:</i></b></p> <p><b>DMSO : 12.5 mg/mL (25.29 mM; Need ultrasonic)</b></p>																	
	<table><tr><td rowspan="4">Preparing Stock Solutions</td><td><div><div>Solvent</div><div>Mass</div><div>Concentration</div></div></td><td>1 mg</td><td>5 mg</td><td>10 mg</td></tr><tr><td>1 mM</td><td>2.0230 mL</td><td>10.1149 mL</td><td>20.2298 mL</td></tr><tr><td>5 mM</td><td>0.4046 mL</td><td>2.0230 mL</td><td>4.0460 mL</td></tr><tr><td>10 mM</td><td>0.2023 mL</td><td>1.0115 mL</td><td>2.0230 mL</td></tr></table>	Preparing Stock Solutions	<div><div>Solvent</div><div>Mass</div><div>Concentration</div></div>	1 mg	5 mg	10 mg	1 mM	2.0230 mL	10.1149 mL	20.2298 mL	5 mM	0.4046 mL	2.0230 mL	4.0460 mL	10 mM	0.2023 mL	1.0115 mL	2.0230 mL
	Preparing Stock Solutions		<div><div>Solvent</div><div>Mass</div><div>Concentration</div></div>	1 mg	5 mg	10 mg												
			1 mM	2.0230 mL	10.1149 mL	20.2298 mL												
			5 mM	0.4046 mL	2.0230 mL	4.0460 mL												
		10 mM	0.2023 mL	1.0115 mL	2.0230 mL													
<p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液 一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。 -80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。</p> <p><b><i>In Vivo:</i></b></p> <p>请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 <b>In Vitro</b> 方式配制澄清的储备液，再依次添加助溶剂：</p> <p>——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶</p> <p>1.请依序添加每种溶剂： 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline</p> <p>Solubility: 1.25 mg/mL (2.53 mM); Suspended solution; Need ultrasonic</p> <p>此方案可获得 1.25 mg/mL (2.53 mM)的均匀悬浊液，悬浊液可用于口服和腹腔注射。</p> <p>以 1 mL 工作液为例，取 100 <math>\mu</math>L 12.5 mg/mL 的澄清 DMSO 储备液加到 400 <math>\mu</math>L PEG300 中，混合均匀；向上述体系中加入 50 <math>\mu</math>L Tween-80，混合均匀；然后继续加入 450 <math>\mu</math>L 生理盐水定容至 1 mL。</p>																		
References	<p>[1]. Wang G, et al. Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. <i>Nat Chem Biol.</i> 2013 Feb;9(2):84-9.</p>																	